Drug Trial Radar · NCT06249152
Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients
Last checked: Nov 19, 2026Latest source record: Jan 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Apr 21, 2024
Primary completion
Dec 20, 2024
Study completion Dec 20, 2024
Sponsor
- Lead sponsor
- Qlaris Bio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Qlaris Phase 2 clinical study investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in combination with latanoprost in open-angle glaucoma (OAG) and/or ocular hypertension (OHT) patients.
Conditions
- Open-angle Glaucoma (OAG)
- Ocular Hypertension (OHT)
- Glaucoma
Interventions
QLS-111, 0.015%Drug
QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.
QLS-111, 0.030%Drug
QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.
QLS-111, 0.075%Drug
QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.
QLS-111 vehicle ophthalmic solutionDrug
Vehicle drops applied QPM for 14 days the BID for 14 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of ocular treatment-emergent adverse events (TEAEs)Time frame: 28 days
- Clinically significant change in visual acuityTime frame: 28 days
- Clinically significant change in findings on slit lamp examTime frame: 28 days
- Clinically significant change in findings on fundus examTime frame: 28 days
- Incidence of systemic (TEAEs)Time frame: 28 days
- Clinically significant change in blood pressureTime frame: 28 days
- Clinically significant change in heart rateTime frame: 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Berkeley Eye Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.